View:
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 12/30/2019 |
3. Issuer Name and Ticker or Trading Symbol
Coherus BioSciences, Inc. [ CHRS ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 7,381,116 | D(1) | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
| Explanation of Responses: |
| 1. V-Sciences Investments Pte Ltd ("V-Sciences") directly owns 7,381,116 shares of Issuer's common stock. V-Sciences is a wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"), which is a wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which is a wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Each of Temasek Life Sciences, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares held by V-Sciences. |
| Remarks: |
| V-SCIENCES INVESTMENTS PTE LTD By: /s/ Zahedah Abdul Rashid, in her capacity as Director of V-Sciences Investments Pte Ltd | 01/08/2020 | |
| TEMASEK LIFE SCIENCES PRIVATE LIMITED By: /s/ Lim Siew Lee Sherlyn, in her capacity as Director of Temasek Life Sciences Private Limited | 01/08/2020 | |
| FULLERTON MANAGEMENT PTE LTD By: /s/ Cheong Kok Tim, in his capacity as Director of Fullerton Management Pte Ltd | 01/08/2020 | |
| TEMASEK HOLDINGS (PRIVATE) LIMITED By: /s/ Andrew Ang Lye Whatt, in his capacity as Authorized Signatory of Temasek Holdings (Private) Limited | 01/08/2020 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||